Pharmacists should reconsider recommending toxic chemotherapy for cancer palliation because it may significantly worsen terminal cancer patients' quality of life near death.
Robert Gaudette, PharmD/MBA Candidate 2016
Advertisement
Articles by Robert Gaudette, PharmD/MBA Candidate 2016
A study evaluating the cardiovascular safety of Merck's type 2 diabetes drug sitagliptin determined the dipeptidyl peptidase-4 inhibitor does not increase the risk for heart failure hospitalization.
Pharmacists know changes in vitamin K intake can drastically alter INR values in patients taking warfarin.
Advertisement
Latest Updated Articles
App Tracks Vitamin K Intake for Warfarin PatientsPublished: June 11th 2015 | Updated:
Diabetes Drug Won't Worsen Heart Failure RiskPublished: June 14th 2015 | Updated:
Palliative Chemo May Worsen QOL Near DeathPublished: August 16th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
3
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
4
Current and Emerging BCMAxCD3 Bispecifics
5
